Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

Summary

The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.

Timeline

Start

2018-05-01

Primary completion

2019-05-28

Completion

2019-08-28

Outcome

Met primary endpoint

registry analysis (superiority test); Placebo vs Actovegin 1200 mg; p = 0.0041; Least square mean difference 29.19 (95% CI 9.35 to 49.02); MMRM NCT03469349 ↗

Drugs

Indications